Inventiva S.A.
Research Inventiva S.A. (0RNK) with Bullrun company financials, valuation charts, model signals, and historical stock context.
Key Metrics
- Ticker0RNK
- ExchangeLSE
- CountryFrance
- CurrencyEUR
About Inventiva S.A.
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses.
Frequently asked questions
What does Inventiva S.A. do?
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally.